Rayldee Trial

    • OUCH!!!! More setbacks.

    • In 2014, Pfizer and OPKO Health Inc (NASDAQ: OPK) entered into a worldwide agreement to develop and commercial somatrogon for GHD.

  • Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.
  • The FDA has pushed back approval of Pfizer's once-weekly prospect.
  • Ascendis Pharma A/D (NASDAQ: ASND), after suffering its regulatory delay, won FDA approval for its once-weekly treatment for pediatric growth hormone deficiency (GHD) last month.
All submissions to the FDA have been delayed due to covid. Not a big deal